Vertaling van "active ingredient in reclast " (Nederlands → Frans) :

Zoledronic acid, the active ingredient in Reclast/Aclasta, is also available under the trade name Zometa for use in oncology indications.
L’acide zolédronique, la substance active d’Aclasta/Reclast, est également disponible sous la marque Zometa pour son utilisation dans les indications oncologiques.

Zoledronic acid, the active ingredient in Zometa, is also available under the trade names Reclast/Aclasta for use in non-oncology indications.
L’acide zolédronique, la substance active de Zometa, est également disponible sous les marques Aclasta/Reclast pour son utilisation dans les indications non oncologiques.

Zoledronic acid, the active ingredient in Zometa (4mg), is also available under the trade names Reclast/Aclasta (5mg) for use in non-oncology indications with different dosing.
L’acide zolédronique, la substance active de Zometa (4mg), est également disponible sous les marques Aclasta/Reclast (5mg) pour son utilisation avec différents dosages dans les indications non oncologiques.

Active pharmacovigilance In the context of the FAMHP’s decision to promote proactive pharmacovigilance, a decision was made at the end of 2007 to encourage healthcare professionals to pay extra attention to adverse effects that arise after taking medicines with a new active ingredient (the “black triangle” project - during
Active pharmacovigilance In the context of the FAMHP’s decision to promote proactive pharmacovigilance, a decision was made at the end of 2007 to encourage healthcare professionals to pay extra attention to adverse effects that arise after taking medicines with a new active ingredient (the “black triangle” project - during

●● Efficacy: the active ingredient is as such subject to an authorisation or prequalification by the WHO or a positive opinion from the EMEA During this first year of activity, The Production & Distribution department issued 149 EDs.
●● Efficacy: the active ingredient is as such subject to an authorisation or prequalification by the WHO or a positive opinion from the EMEA During this first year of activity, The Production & Distribution department issued 149 EDs.

We adopt a risk-based approach and focus on minimizing our use of natural resources, cutting our energy consumption and emissions, and preventing active ingredients from entering the environment.
Notre approche est basée sur une évaluation des risques ; nous nous efforçons de réduire au minimum notre exploitation des ressources naturelles, d’abaisser notre consommation d’énergie et nos émissions de gaz polluants dans l’air, et nous prenons toutes les mesures adéquates pour empêcher les émanations de substances actives en dehors de nos laboratoires.

Our production processes are optimized so as to minimize the release of active ingredients into the environment.
De même, nous optimisons nos méthodes de production de sorte à minimiser le rejet de substances actives dans l’environnement.

The active ingredient, everolimus, is the same as in the transplant therapy Certican.
Evérolimus est la substance active de Certican, un traitement utilisé dans les transplantations.

medicines for human use and veterinary medicines, raw materials (active ingredients) for pharmacists, establishment of retail pharmacies, medical devices) ●● Management of possible crisis situations ●● Coordination of the (inter)national representation of the FAMHP ●● The difference between the roles of “Communication” versus “Information” ●● Points of entry for applications submitted to
medicines for human use and veterinary medicines, raw materials (active ingredients) for pharmacists, establishment of retail pharmacies, medical devices) ●● Management of possible crisis situations ●● Coordination of the (inter)national representation of the FAMHP ●● The difference between the roles of “Communication” versus “Information” ●● Points of entry for applications submitted to

The active ingredient of this medicine is covered by a compound patent that expires in 2010 in the US.
La substance active de ce médicament est couverte par un brevet qui expire en 2010 dans ce pays.